HOME >> BIOLOGY >> NEWS
Aggressive therapy best for certain AML patients

COLUMBUS , Ohio A new study suggests that acute leukemia patients whose cancer cells show a genetic change that usually predicts a swift return of the disease following remission may remain disease-free longer when given aggressive therapy.

The findings apply to people with acute myeloid leukemia (AML) whose cancer cells have normal-looking chromosomes and a gene mutation called MLL-PTD.

Typically, these AML patients responded poorly following treatment with older standard therapies, often relapsing within a year. Of AML patients with normal chromosomes who lack the mutation, on the other hand, four in 10 are cured.

The new study suggests that treating patients who have the mutation with an aggressive therapy such as an autologous stem cell transplant while they are in remission might significantly extend their disease-free survival.

An autologous transplant uses stem cells taken from the patient's own blood.

The research was led by investigators at the Ohio State University Comprehensive Cancer Center. It is part of a larger study sponsored by the Cancer and Leukemia Group B (CALGB), a clinical cooperative group composed of oncologists from academic medical centers and community hospitals across the nation.

The findings were published in a recent issue of the journal Blood.

Our data is the first to show that AML patients with normal-looking chromosomes and this mutation do as well when treated aggressively as patients who don't have the mutation, says principal investigator Clara D. Bloomfield, professor of internal medicine and an internationally known AML specialist.

About 13,400 new cases of AML are expected this year, and about half will have cancer cells with chromosomes that show distinctive damage. The nature of that damage helps doctors determine a patient's therapy and estimate the patient's prognosis.

The remaining AML cases have cancer cells with normal
'"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-293-2092
Ohio State University
1-Aug-2007


Page: 1 2

Related biology news :

1. Aggressive subtype of breast cancer displays misbehavior of X chromosomes
2. Aggressive aquatic species invading Great Lakes
3. Testosterone replacement therapy: How safe for aging men?
4. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
5. Under magnetic force, nanoparticles may deliver gene therapy
6. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Stem cell therapy rescues motor neurons in ALS model
8. Study identifies new gene therapy tools for inherited blindness
9. Breast cancer and hormone therapy -- A looking-glass mirror?
10. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
11. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/26/2019)... ... October 24, 2019 , ... World Cord Blood Day (WCBD) takes place on ... to learn about the current and future uses of cord blood stem cells, and ... used to treat and cure over 80 different life-threatening diseases, including leukemia, lymphoma, and ...
(Date:10/26/2019)... ... October 25, 2019 , ... The ... in La Plata, MD. Orofacial myofunctional disorders (OMDs) are abnormal movement patterns of ... speaks. This can include anything from difficulty swallowing and limited tongue movement to ...
(Date:10/22/2019)... , ... October 22, 2019 , ... Greenberg Traurig, ... seminar, “Insiders’ Views of Deal Making in the Life Sciences Sector,” with German biotech ... on Oct. 25, 2019, at Greenberg Traurig’s Tokyo office . , Speakers from ...
Breaking Biology News(10 mins):
(Date:10/22/2019)... , ... October 22, 2019 , ... ... has announced that its lead program, DBI-001, met its primary safety endpoints, with ... labeled phase 2a clinical trial for the treatment of interdigital tinea pedis (athlete’s ...
(Date:10/17/2019)... ... October 16, 2019 , ... ... easy-to-understand, web-based genetic counseling information, has published a new white paper that explores ... and provides guidance as to how patients and medical providers can be kept ...
(Date:10/10/2019)... Md. (PRWEB) , ... October 09, 2019 , ... ... announced Amy Abernethy, MD, PhD, Principal Deputy Commissioner, FDA, as a newly-confirmed keynote ... 27–30 October 2019 in Las Vegas, Nevada USA. , Dr. Abernethy, a hematologist/oncologist ...
(Date:10/10/2019)... (PRWEB) , ... October 10, 2019 , ... R3 Stem ... The next course is October 18-19th, 2019 in Las Vegas with spots still open. ... He completed training at several Ivy League universities including Cornell, Harvard and Dartmouth. He ...
Breaking Biology Technology:
Cached News: